Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection

Ariela Benigni, Susanna Tomasoni, Laurence A. Turka, Lorena Longaretti, Lorena Zentilin, Marilena Mister, Anna Pezzotta, Nadia Azzollini, Marina Noris, Sara Conti, Mauro Abbate, Mauro Giacca, Giuseppe Remuzzi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Short-term results of renal transplantation have improved considerably in the past 20 yr; however, similar improvements in long-term outcome have not been achieved. The primary cause of late graft loss is chronic rejection that might be treated by gene therapeutic approaches. Ideally, one would like to impair locally the contact between transplant antigen and the host immune system without compromising the generalized immune competence of the recipient. This can be achieved by local expression of the therapeutic protein in the site of interest using gene therapy. Here it is shown that chronic allograft rejection can be prevented effectively by local delivery of recombinant adeno-associated virus (AAV) vectors that encode the CTLA4Ig immunosuppressant protein to the donor kidney in a fully MHC-mismatched rat strain combination. AAV CTLA4Ig prevented progressive proteinuria and protected transplant kidneys from renal structural injury. A population of anergic T cells with regulatory activity, which eventually were responsible for the induction of tolerance, were found in recipient lymph nodes and in the graft as long as 120 d after transplantation. These data indicate that AAV-mediated CTLA4Ig gene transfer to donor graft represents a promising tool to prevent the onset of chronic rejection and circumvent the unwanted systemic adverse effects of the administration of immunomodulatory protein.

Original languageEnglish
Pages (from-to)1665-1672
Number of pages8
JournalJournal of the American Society of Nephrology
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Dependovirus
Allografts
Transplants
Kidney
Genes
Proteins
Regulatory T-Lymphocytes
Immunosuppressive Agents
Proteinuria
Genetic Therapy
Kidney Transplantation
Mental Competency
Immune System
Transplantation
Lymph Nodes
Rejection (Psychology)
Antigens
Wounds and Injuries
Therapeutics
Population

ASJC Scopus subject areas

  • Nephrology

Cite this

Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. / Benigni, Ariela; Tomasoni, Susanna; Turka, Laurence A.; Longaretti, Lorena; Zentilin, Lorena; Mister, Marilena; Pezzotta, Anna; Azzollini, Nadia; Noris, Marina; Conti, Sara; Abbate, Mauro; Giacca, Mauro; Remuzzi, Giuseppe.

In: Journal of the American Society of Nephrology, Vol. 17, No. 6, 06.2006, p. 1665-1672.

Research output: Contribution to journalArticle

Benigni, Ariela ; Tomasoni, Susanna ; Turka, Laurence A. ; Longaretti, Lorena ; Zentilin, Lorena ; Mister, Marilena ; Pezzotta, Anna ; Azzollini, Nadia ; Noris, Marina ; Conti, Sara ; Abbate, Mauro ; Giacca, Mauro ; Remuzzi, Giuseppe. / Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. In: Journal of the American Society of Nephrology. 2006 ; Vol. 17, No. 6. pp. 1665-1672.
@article{5e205903d0af43c5ac1958372fe1875c,
title = "Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection",
abstract = "Short-term results of renal transplantation have improved considerably in the past 20 yr; however, similar improvements in long-term outcome have not been achieved. The primary cause of late graft loss is chronic rejection that might be treated by gene therapeutic approaches. Ideally, one would like to impair locally the contact between transplant antigen and the host immune system without compromising the generalized immune competence of the recipient. This can be achieved by local expression of the therapeutic protein in the site of interest using gene therapy. Here it is shown that chronic allograft rejection can be prevented effectively by local delivery of recombinant adeno-associated virus (AAV) vectors that encode the CTLA4Ig immunosuppressant protein to the donor kidney in a fully MHC-mismatched rat strain combination. AAV CTLA4Ig prevented progressive proteinuria and protected transplant kidneys from renal structural injury. A population of anergic T cells with regulatory activity, which eventually were responsible for the induction of tolerance, were found in recipient lymph nodes and in the graft as long as 120 d after transplantation. These data indicate that AAV-mediated CTLA4Ig gene transfer to donor graft represents a promising tool to prevent the onset of chronic rejection and circumvent the unwanted systemic adverse effects of the administration of immunomodulatory protein.",
author = "Ariela Benigni and Susanna Tomasoni and Turka, {Laurence A.} and Lorena Longaretti and Lorena Zentilin and Marilena Mister and Anna Pezzotta and Nadia Azzollini and Marina Noris and Sara Conti and Mauro Abbate and Mauro Giacca and Giuseppe Remuzzi",
year = "2006",
month = "6",
doi = "10.1681/ASN.2006010090",
language = "English",
volume = "17",
pages = "1665--1672",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "6",

}

TY - JOUR

T1 - Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection

AU - Benigni, Ariela

AU - Tomasoni, Susanna

AU - Turka, Laurence A.

AU - Longaretti, Lorena

AU - Zentilin, Lorena

AU - Mister, Marilena

AU - Pezzotta, Anna

AU - Azzollini, Nadia

AU - Noris, Marina

AU - Conti, Sara

AU - Abbate, Mauro

AU - Giacca, Mauro

AU - Remuzzi, Giuseppe

PY - 2006/6

Y1 - 2006/6

N2 - Short-term results of renal transplantation have improved considerably in the past 20 yr; however, similar improvements in long-term outcome have not been achieved. The primary cause of late graft loss is chronic rejection that might be treated by gene therapeutic approaches. Ideally, one would like to impair locally the contact between transplant antigen and the host immune system without compromising the generalized immune competence of the recipient. This can be achieved by local expression of the therapeutic protein in the site of interest using gene therapy. Here it is shown that chronic allograft rejection can be prevented effectively by local delivery of recombinant adeno-associated virus (AAV) vectors that encode the CTLA4Ig immunosuppressant protein to the donor kidney in a fully MHC-mismatched rat strain combination. AAV CTLA4Ig prevented progressive proteinuria and protected transplant kidneys from renal structural injury. A population of anergic T cells with regulatory activity, which eventually were responsible for the induction of tolerance, were found in recipient lymph nodes and in the graft as long as 120 d after transplantation. These data indicate that AAV-mediated CTLA4Ig gene transfer to donor graft represents a promising tool to prevent the onset of chronic rejection and circumvent the unwanted systemic adverse effects of the administration of immunomodulatory protein.

AB - Short-term results of renal transplantation have improved considerably in the past 20 yr; however, similar improvements in long-term outcome have not been achieved. The primary cause of late graft loss is chronic rejection that might be treated by gene therapeutic approaches. Ideally, one would like to impair locally the contact between transplant antigen and the host immune system without compromising the generalized immune competence of the recipient. This can be achieved by local expression of the therapeutic protein in the site of interest using gene therapy. Here it is shown that chronic allograft rejection can be prevented effectively by local delivery of recombinant adeno-associated virus (AAV) vectors that encode the CTLA4Ig immunosuppressant protein to the donor kidney in a fully MHC-mismatched rat strain combination. AAV CTLA4Ig prevented progressive proteinuria and protected transplant kidneys from renal structural injury. A population of anergic T cells with regulatory activity, which eventually were responsible for the induction of tolerance, were found in recipient lymph nodes and in the graft as long as 120 d after transplantation. These data indicate that AAV-mediated CTLA4Ig gene transfer to donor graft represents a promising tool to prevent the onset of chronic rejection and circumvent the unwanted systemic adverse effects of the administration of immunomodulatory protein.

UR - http://www.scopus.com/inward/record.url?scp=33646945877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646945877&partnerID=8YFLogxK

U2 - 10.1681/ASN.2006010090

DO - 10.1681/ASN.2006010090

M3 - Article

C2 - 16641148

AN - SCOPUS:33646945877

VL - 17

SP - 1665

EP - 1672

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 6

ER -